Abstract
INTRODUCTION:Parkinsonism is a clinical syndrome characterized by tremor, rigidity, and bradykinesia due to alteration in the basal-ganglia dopaminergic circuit, specifically at the nigrostriatal level. The following is a case of parkinsonism induced by telmisartan.
CASE PRESENTATION:A 78-year-old man with a 2-year history of Parkinson's disease of controlled evolution with levodopa, pramipexole ER, amantadine was admitted to the emergency department due to worsening of parkinsonism in the two weeks prior to consultation. He had a history of cerebral infarction in the territory of the left posterior cerebral artery, chronic arterial hypertension, and type 2 diabetes mellitus. On neurological examination, he presented bradykinesia and severe stiffness in all four limbs with significant limitation of gait, associated with myoclonus. Infectious and metabolic alterations and acute lesions were ruled out in the brain tomography, so telmisartan was suspended, after which the symptoms improved.
DISCUSSION:Drug-induced parkinsonism is the first cause of this syndrome, and the action they exert on dopaminergic receptors has been described in several pharmacological models. Telmisartan-induced parkinsonism is considered triggered by dopaminergic disruption secondary to angiotensin II receptor antagonism at the periaqueductal gray substance level.
References
Saavedra-Moreno JS, Millán PA, Buriticá-Henao OF. Introducción, epidemiología y diagnóstico de la enfermedad de Parkinson. Acta Neurol Colomb. 2019;35(3 Supl. 1):2-10. http://dx.doi.org/10.22379/24224022244.
Tisch S, Silberstein P, Limousin-Dowsey P, Jahanshahi M. The basal ganglia: anatomy, physiology, and pharmacology. Psychiatr Clin North Am. 2004;27(4):757-99. http://dx.doi.org/10.1016/j.psc.2004.06.004
Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and associated with tardive dyskinesia. J Clin Psychopharmacol. 1999;19(3):203-8. http://dx.doi.org/10.1097/00004714-199906000-00002
Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE, et al. Role of the renin-angiotensin-aldosterone system beyond blood pressure regulation: molecular and cellular mechanisms involved in end-organ damage during arterial hypertension. Int J Mol Sci. 2016;17(7):pii:E797. http://dx.doi.org/10.3390/ijms17070797.
Marti-Massó JF, Poza JJ, López de Munain A. Drugs inducing or aggravating Parkinsonism: a review. Therapie. 1996;51(5):568-77.
García de Francisco A, García de Francisco S, Prieto Zancudo C. Parkinsonismo inducido por fármacos. FMC. 2002;9(4):283-9. htpp://dx.doi.org/10.1016/S1134-2072(02)75585-0.
Labandeira-Garcia JL, Rodríguez Perez AI, Garrido-Gil P, Rodríguez-Pallares J, Lanciego JL, Guerra MJ. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front Aging Neurosci. 2017;9:129. htpp://dx.doi.org/10.3389/fnagi.2017.00129.
Rodríguez-Pallares J, Quiroz CR, Parga, JA, Guerra MJ, Labandeira-García JL, Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci. 2004;20(6):1489-98. htpp://dx.doi.org/10.1111/j.1460-9568.2004. 03621.x
Zalba, G, San José G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, et al. Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension. 2001;38(6):1395-9. htpp://dx.doi.org/10.1161/hy1201.099611
Rodríguez-Pérez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, et al. Angiotensin type 1 receptor antagonists protect against alpha-synuclein-induced neuroinflammation and dopaminergic neuron death. Neuro-therapeutics. 2018;15(4):1063-81. htpp://dx.doi.org/10.1007/s13311-018-0646-z.
Sekar S, Mani S, Barathidasan R, Manivasagam T, Thenmozhi A, Bhat A, et al. Telmisartan ameliorates astroglial and dopaminergic functions in a mouse model of chronic Parkinsonism. Neurotox Res. 2018;34:597-612.
Morabito BD, Paulison B. Drug-induced parkinsonism: A case report. Ment Health Clin. 2018;7(2):65-8. htpp://dx.doi. org/10.9740/mhc.2017.03.065.
Shiraiwa N, Tamaoka A, Ohkoshi N. Clinical features of drug-induced Parkinsonism. Neurol Int. 2018;10(4):7877. htpp://dx.doi.org/10.4081/ni.2018.7877.
Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr Med Res Opin. 2003;19(5):449-51. htpp://dx.doi.org/10.1185/030079903125001974.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.